SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria

Since December 2019 the world has been dealing with a severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. The first SARS-CoV-2 vaccine was made available in Europe at the end of 2020. 202 volunteers from the vicinity of the University of Applied Sciences Wiener Neustadt took...

Descripción completa

Detalles Bibliográficos
Autores principales: Mara, Elisabeth, Mader, Tobias, Gratzer, Johannes, Hochegger, Stefanie, Pekar, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472700/
https://www.ncbi.nlm.nih.gov/pubmed/38013972
http://dx.doi.org/10.1016/j.clicom.2022.08.001
_version_ 1784789350570000384
author Mara, Elisabeth
Mader, Tobias
Gratzer, Johannes
Hochegger, Stefanie
Pekar, Thomas
author_facet Mara, Elisabeth
Mader, Tobias
Gratzer, Johannes
Hochegger, Stefanie
Pekar, Thomas
author_sort Mara, Elisabeth
collection PubMed
description Since December 2019 the world has been dealing with a severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. The first SARS-CoV-2 vaccine was made available in Europe at the end of 2020. 202 volunteers from the vicinity of the University of Applied Sciences Wiener Neustadt took part in this study; their IgG levels recognizing the RBD of SARS-CoV-2 were determined. The aim was to evaluate the SARS-CoV-2 titer levels of vaccinated, recovered and vaccinated plus recovered persons. We could show that there is a significant difference in the antibody levels of vaccinated, vaccinated plus recovered and only recovered probands. Additionally, the highest antibody levels were found in triple vaccinated persons. Furthermore, the Moderna vaccine seems to have a higher immune response.
format Online
Article
Text
id pubmed-9472700
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-94727002022-09-14 SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria Mara, Elisabeth Mader, Tobias Gratzer, Johannes Hochegger, Stefanie Pekar, Thomas Clinical Immunology Communications Short Communication Since December 2019 the world has been dealing with a severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. The first SARS-CoV-2 vaccine was made available in Europe at the end of 2020. 202 volunteers from the vicinity of the University of Applied Sciences Wiener Neustadt took part in this study; their IgG levels recognizing the RBD of SARS-CoV-2 were determined. The aim was to evaluate the SARS-CoV-2 titer levels of vaccinated, recovered and vaccinated plus recovered persons. We could show that there is a significant difference in the antibody levels of vaccinated, vaccinated plus recovered and only recovered probands. Additionally, the highest antibody levels were found in triple vaccinated persons. Furthermore, the Moderna vaccine seems to have a higher immune response. Published by Elsevier Inc. 2022-12 2022-09-14 /pmc/articles/PMC9472700/ /pubmed/38013972 http://dx.doi.org/10.1016/j.clicom.2022.08.001 Text en © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Mara, Elisabeth
Mader, Tobias
Gratzer, Johannes
Hochegger, Stefanie
Pekar, Thomas
SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria
title SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria
title_full SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria
title_fullStr SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria
title_full_unstemmed SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria
title_short SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria
title_sort sars-cov-2 antibody determination in a vaccinated and recovered cohort in austria
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472700/
https://www.ncbi.nlm.nih.gov/pubmed/38013972
http://dx.doi.org/10.1016/j.clicom.2022.08.001
work_keys_str_mv AT maraelisabeth sarscov2antibodydeterminationinavaccinatedandrecoveredcohortinaustria
AT madertobias sarscov2antibodydeterminationinavaccinatedandrecoveredcohortinaustria
AT gratzerjohannes sarscov2antibodydeterminationinavaccinatedandrecoveredcohortinaustria
AT hocheggerstefanie sarscov2antibodydeterminationinavaccinatedandrecoveredcohortinaustria
AT pekarthomas sarscov2antibodydeterminationinavaccinatedandrecoveredcohortinaustria

Ejemplares similares